1. Home
  2. NEGG vs CDXS Comparison

NEGG vs CDXS Comparison

Compare NEGG & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newegg Commerce Inc.

NEGG

Newegg Commerce Inc.

HOLD

Current Price

$54.71

Market Cap

1.6B

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.67

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEGG
CDXS
Founded
2001
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Major Chemicals
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
141.8M
IPO Year
2010
2010

Fundamental Metrics

Financial Performance
Metric
NEGG
CDXS
Price
$54.71
$1.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
146.9K
1.1M
Earning Date
12-01-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,313,127,000.00
$52,932,000.00
Revenue This Year
N/A
$15.64
Revenue Next Year
N/A
$5.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.32
$1.52
52 Week High
$137.84
$5.51

Technical Indicators

Market Signals
Indicator
NEGG
CDXS
Relative Strength Index (RSI) 38.15 42.82
Support Level $53.32 $1.61
Resistance Level $59.21 $1.75
Average True Range (ATR) 5.06 0.09
MACD -1.64 0.01
Stochastic Oscillator 8.39 18.57

Price Performance

Historical Comparison
NEGG
CDXS

About NEGG Newegg Commerce Inc.

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: